Open Access
Issue
BIO Web Conf.
Volume 129, 2024
The 17th European Microscopy Congress (EMC 2024)
Article Number 21005
Number of page(s) 2
Section CryoEM from Membrane Proteins to Large Complexes
DOI https://doi.org/10.1051/bioconf/202412921005
Published online 17 October 2024
  • Serrano, M. A., Furman, R., Chen, G., & Tao, L. (2023). Mass spectrometry in gene therapy: Challenges and opportunities for AAV analysis. Drug Discovery Today, 28(1), 103442. [CrossRef] [PubMed] [Google Scholar]
  • Bijlani, S., Pang, K. M., Sivanandam, V., Singh, A., & Chatterjee, S. (2022). The role of recombinant AAV in precise genome editing. Frontiers in Genome Editing, 3, 799722. [CrossRef] [PubMed] [Google Scholar]
  • Grimm, D., & Kay, M. A. (2003). From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Current gene therapy, 3(4), 281–304 [CrossRef] [PubMed] [Google Scholar]
  • Stagg, S. M., Yoshioka, C., Davulcu, O., & Chapman, M. S. (2022). Cryo-electron microscopy of adeno-associated virus. Chemical Reviews, 122(17), 14018–14054 [CrossRef] [PubMed] [Google Scholar]
  • Colomb-Delsuc, M., Raim, R., Fiedler, C., Reuberger, S., Lengler, J., Nordström, R., … & Sintorn, I. M. (2022). Assessment of the percentage of full recombinant adeno-associated virus particles in a gene therapy drug using CryoTEM. PloS one, 17(6), e0269139. [CrossRef] [PubMed] [Google Scholar]
  • Wright, J. F. (2014). AAV empty capsids: for better or for worse?. Molecular Therapy, 22(1), 1–2 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.